This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 3
  • /
  • Health Canada approves Kesimpta to treat relapsing...

Health Canada approves Kesimpta to treat relapsing remitting multiple sclerosis. Novartis

Read time: 1 mins
Published:26th Mar 2021
Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Kesimpta (ofatumumab) for the treatment of adults with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features. Kesimpta is the first and only targeted B-cell therapy that can be self-administered subcutaneously once a month via the Sensoready autoinjector pen.
Condition: Multiple Sclerosis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.